Reverse shoulder arthroplasty has become the standard treatment for cuff tear arthropathy and complex fractures of the proximal humerus. The Delta Xtend prosthesis (DePuy Synthes, Warsaw, IN, USA) was launched in 2006 and has shown good short-term results. Longer-term results are not yet available. There were 126 primary Delta Xtend prostheses implanted in our center by 1 surgeon from October 2006 until December 2009. Of these, 38 patients died, 12 were lost to follow-up, and 2 needed early revision of the prosthesis. Follow-up of at least 8 years was available for 74 patients. At preoperative and postoperative visits, shoulder function and pain were evaluated using the age- and sex-adjusted Constant-Murley score (aCS). The satisfaction rate was evaluated on a visual analog scale (VAS). The mean follow-up in our population was 113.1 months. The mean aCS was 44.6% (standard deviation [SD], 19.2) preoperatively. It increased significantly (P < .001) after surgery to 75.8% (SD, 12.5) at 3 months and 91.1% (SD, 11.8) at 5 years. At the latest follow-up, the mean aCS was only 79.9% (SD, 17.7), which was significantly lower (P = .002) than the aCS at 5 years postoperatively. An overall survival rate of more than 97% was seen at 8 years of follow-up. This study confirms that the promising short-term results of the Delta Xtend prosthesis can be extended in the longer-term. However, further follow-up will be necessary to check whether the statistically significant decrease in the Constant-Murley score at latest follow-up, which was driven by a decrease in range of motion and power, continues or not. Copyright © 2018 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.